Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4-5 lesions [0.03%]
同侧取样可维持临床显著性癌症的检出并减少PI-RADS 4-5病变的过度诊断
Cassandra Jeavons,Kevin An,Yilin Zhang et al.
Cassandra Jeavons et al.
Background: Men with unilateral PI-RADS 4-5 lesions routinely undergo targeted and systematic biopsy, increasing detection of clinically insignificant cancer (ciPCa). Whether contralateral systematic cores add meaningful ...
Testis-sparing surgery for small testicular masses: Functional and oncological outcomes [0.03%]
小睾丸肿物的保留睾丸功能手术:功能和肿瘤结局评估
Oğuzhan Kahraman,Bülent Akdoğan
Oğuzhan Kahraman
Purpose: To evaluate functional and oncological outcomes of testis-sparing surgery (TSS), particularly in selected patients with small testicular masses (STMs), including those with a normal contralateral testis and germ ...
Subcapsular versus total orchiectomy in advanced prostate cancer: A systematic review and meta-analysis of clinical and patient-reported outcomes [0.03%]
前列腺癌根治术中亚肾被膜与睾丸全切效果的系统评价和meta分析:临床结果及患者报告结果的比较
Angga D M Pratama,Steven A Shenelo,Rizqi A F Kamila et al.
Angga D M Pratama et al.
Background: Prostate cancer (CaP) is a leading malignancy in men, frequently diagnosed at advanced stages where androgen deprivation therapy remains the standard treatment. Surgical castration, either subcapsular or total...
Jodi K Maranchie
Jodi K Maranchie
Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models [0.03%]
基于隐私保护的本地大型语言模型在前列腺癌活检和病理报告标准化中的应用自动化
Rohit Malyala,Takeshi Namekawa,Anna Black et al.
Rohit Malyala et al.
Purpose: Large-scale biomedical analysis in prostate cancer requires structured, tabular datasets, yet most clinical documentation remains in free-text format. The standard of manual data abstraction is time-consuming, er...
Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio [0.03%]
俄亥俄州工业塑料排放与膀胱癌和肾癌负担的地理空间关联
Devika Nandwana,Jayant Siva,Laura Davis et al.
Devika Nandwana et al.
Background: While several environmental carcinogens are well-established in the development of bladder and kidney cancer, the role of microplastic exposure remains poorly understood. Micro- and nanoplastics (MNPs), often ...
Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-Guérin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled cohort clinical study [0.03%]
预测 Toll 样受体、髓系分化因子 88 和核因子 κB 关于高危非肌层浸润性膀胱癌患者卡介苗腔内治疗应答的价值:一项队列临床研究
Aya A Zahran,Ahmed A Shokeir,Mohamed Saad Serria et al.
Aya A Zahran et al.
Background: Intravesical Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Toll-like receptors (TLRs) modulate the BCG immune response. Myeloid d...
Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis [0.03%]
抗糖尿病药物与糖尿病患者的膀胱癌风险:系统评价和荟萃分析
Dong Lei,Jin-H Wu,Xi-H Zeng et al.
Dong Lei et al.
Bladder cancer (BC) is the most common malignancy of the urinary system worldwide. Type 2 diabetes mellitus (T2DM) and its treatments may influence BC risk, but existing evidence is conflicting. This study aimed to systematically evaluate t...
The Paris System for reporting urinary cytology in the follow-up of non-muscle-invasive bladder cancer [0.03%]
巴黎系统:非肌层浸润性膀胱癌随访尿液细胞学报告体系
Otto Jokelainen,Liida Ruotsalainen,Essi Ikonen et al.
Otto Jokelainen et al.
Introduction: This study aimed to investigate the correlation between the Paris System for Reporting Urinary Cytology (TPS) and cystoscopic findings in histologically confirmed bladder cancer recurrences. We also assessed...
Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study [0.03%]
一项多中心真实世界研究:EVITA与晚期尿路上皮癌安全性的关联性分析
Keita Ishimoto,Takuma Narita,Yuya Sekine et al.
Keita Ishimoto et al.
Objective: To evaluate whether the EV-ineligible criteria (EVITA) are associated with severe adverse events (AEs) and early treatment discontinuation in patients with locally advanced or metastatic urothelial carcinoma (l...